Technology area: Biotechnology & Pharmaceuticals
7 pending office actions • 5 art units • 6 examiners • 0 of 7 (0%) have an AI response strategy ready • 4 patents granted in the last 365 days
Grifols Worldwide Operations Limited has 7 pending office actions in Biotechnology & Pharmaceuticals. The work spans 6 distinct examiners and 5 distinct art units, indicating substantial dispersion across the prosecution portfolio. This structure creates a coordination challenge: counsel must track multiple examination relationships while also identifying issues that recur within shared art-unit assignments.
DABKOWSKI, ERINNE R is the busiest examiner, with 2 pending matters. The remaining pending work is distributed among other examiners, so the profile supports a dual approach. Counsel can develop an examiner-specific strategy for Dabkowski’s matters while using common technical positions, disclosure support, and claim terminology across the broader biotechnology and pharmaceutical docket. Art-unit-level comparisons may help distinguish recurring examination concerns from matters that are unique to individual applications.
Based on the USPTO statutory response window for each pending office action. 5 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 5 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 2 (29%) |
| §102 only | 2 (29%) |
| Double-patenting + other | 2 (29%) |
| Multi-statute (no §101) | 1 (14%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| DABKOWSKI, ERINNE R | 2 | 55.8% | +68.7% |
| REYNOLDS, FRED H | 1 | 32.9% | +39.3% |
| D' AMBROSIO, THEA | 1 | 55.5% | +56.2% |
| YAO, LEI | 1 | 59.7% | +65.3% |
| BALLARD, KIMBERLY | 1 | 53.6% | +49.5% |
| MENON, KRISHNAN S | 1 | 59.7% | +11.3% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18548545 | ALPHA-1 ANTITRYPSIN DOSING REGIMEN | REYNOLDS, FRED H | 60d |
| 18000380 | HYPERIMMUNE IGG AND/OR IGM COMPOSITIONS AND METHOD FOR PREPARING THEREOF AND METHOD FOR OBTAINING HYPERIMMUNE HUMAN PLASMA FROM A DONOR | YAO, LEI | 78d |
| 17809524 | IN VITRO DIAGNOSTIC METHOD FOR ALZHEIMER'S DISEASE BASED ON THE ALBUMIN REDOX LEVEL IN THE CEREBROSPINAL FLUID | BALLARD, KIMBERLY | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 7 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18004233 | COMPOSITIONS HAVING NEUROREGENERATIVE APPLICATIONS | D' AMBROSIO, THEA | 25d overdue |
| 18543196 | USE OF LOW VOLUME PLASMA EXCHANGE FOR TREATING THE EARLY AND MIDDLE STAGES OF ALZHEIMER'S DISEASE | DABKOWSKI, ERINNE R | 7d |
| 18548545 | ALPHA-1 ANTITRYPSIN DOSING REGIMEN | REYNOLDS, FRED H | 60d |
| 18004231 | COMPOSITIONS HAVING NEUROREGENERATIVE APPLICATIONS | DABKOWSKI, ERINNE R | 75d |
| 18000380 | HYPERIMMUNE IGG AND/OR IGM COMPOSITIONS AND METHOD FOR PREPARING THEREOF AND METHOD FOR OBTAINING HYPERIMMUNE HUMAN PLASMA FROM A DONOR | YAO, LEI | 78d |
| 17809524 | IN VITRO DIAGNOSTIC METHOD FOR ALZHEIMER'S DISEASE BASED ON THE ALBUMIN REDOX LEVEL IN THE CEREBROSPINAL FLUID | BALLARD, KIMBERLY | — |
| 17631819 | METHOD FOR CONTROLLING THE AMOUNT OF ANTICOAGULANT PRESENT IN COLLECTED PLASMA AFTER APHERESIS | MENON, KRISHNAN S | — |
| Art Unit | Apps |
|---|---|
| 1654 | 3 |
| 1658 | 1 |
| 1642 | 1 |
| 1649 | 1 |
| 1777 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18543196 | USE OF LOW VOLUME PLASMA EXCHANGE FOR TREATING THE EARLY AND MIDDLE STAGES OF ALZHEIMER'S DISEASE | DABKOWSKI, ERINNE R | 1654 | §102DP | Final Rejection | 7d | Pending | Dec 18, 2023 |
| 18548545 | ALPHA-1 ANTITRYPSIN DOSING REGIMEN | REYNOLDS, FRED H | 1658 | §103§112Other | Non-Final OA | 60d | Pending | Aug 31, 2023 |
| 18004233 | COMPOSITIONS HAVING NEUROREGENERATIVE APPLICATIONS | D' AMBROSIO, THEA | 1654 | §102§103§112DP | Final Rejection | 25d overdue | Pending | Jan 04, 2023 |
| 18004231 | COMPOSITIONS HAVING NEUROREGENERATIVE APPLICATIONS | DABKOWSKI, ERINNE R | 1654 | §102Other | Non-Final OA | 75d | Pending | Jan 04, 2023 |
| 18000380 | HYPERIMMUNE IGG AND/OR IGM COMPOSITIONS AND METHOD FOR PREPARING THEREOF AND METHOD FOR OBTAINING HYPERIMMUNE HUMAN PLASMA FROM A DONOR | YAO, LEI | 1642 | §101§102§103 | Non-Final OA | 78d | Pending | Nov 30, 2022 |
| 17809524 | IN VITRO DIAGNOSTIC METHOD FOR ALZHEIMER'S DISEASE BASED ON THE ALBUMIN REDOX LEVEL IN THE CEREBROSPINAL FLUID | BALLARD, KIMBERLY | 1649 | §101§102§112 | Non-Final OA | — | Pending | Jun 28, 2022 |
| 17631819 | METHOD FOR CONTROLLING THE AMOUNT OF ANTICOAGULANT PRESENT IN COLLECTED PLASMA AFTER APHERESIS | MENON, KRISHNAN S | 1777 | §102 | Final Rejection | — | Pending | Jan 31, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialGrifols Worldwide Operations Limited has 7 pending office actions as of October 2026, spread across 5 art units and 6 examiners.
Erinne R Dabkowski has the most, with 2 of Grifols Worldwide Operations Limited's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
